Edition:
United Kingdom

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

51.90USD
22 Jun 2018
Change (% chg)

$-0.43 (-0.82%)
Prev Close
$52.33
Open
$52.45
Day's High
$52.45
Day's Low
$51.37
Volume
1,255,951
Avg. Vol
129,963
52-wk High
$55.94
52-wk Low
$32.96

Select another date:

Thu, May 3 2018

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​

* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY

BRIEF-Emergent Biosolutions To Implement Stock Repurchase Program

* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK

BRIEF-Emergent Biosolutions Awarded One-Year CDC Contract Valued At $26 Mln

* EMERGENT BIOSOLUTIONS AWARDED ONE-YEAR CDC CONTRACT VALUED AT $26 MILLION FOR VACCINIA IMMUNE GLOBULIN PROGRAM

BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67

* EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS

BRIEF-Emergent Biosolutions Sees FY 2017 Revenue $555 Million To $560 Million

* EMERGENT BIOSOLUTIONS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 FINANCIAL OUTLOOK

Select another date: